The trade group argues CMS exceeded its authority with GLOBE, a Medicare Part B model tying drug rebates to prices in 19 other countries.
News|Articles|December 1, 2004
Government, industry provide pharmaceutical policy outlook for 2005 and beyond
Government, industry provide pharmaceutical policy outlook for 2005; $139 million to advance information technology, records; Rofecoxib hearings point to failures in clinical testing design, decision-making transparency; New guidance for generic drugs clarifies protocol, increases speed to market
Advertisement
Advertisement
Related to this article
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.
Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.
The 2026 American Academy of Ophthalmology Meeting got started today in New Orleans with a mix of celebration and candor about the challenges facing ophthalmology today.
How LLM decision support reshapes dermatology care, helping non-specialists diagnose while navigating trust gaps, ambiguity, and hallucination risks at Fall Clinical Derm.
Real-world data at the 2026 Fall Clinical Dermatology Conference show dupilumab in children with atopic dermatitis cuts new allergies and asthma risk versus steroids.
Sagimet CEO David Happel shares insights on denifanstat, highlighting strong acne response, tolerability and optimism for a denifanstat U.S. trial.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
A conversation about the cycle of ADHD and sleep problems in children, with Alison Pritchard, Ph.D.
2
AI could utterly transform healthcare. But reduce its cost? Perhaps not so much.
3
PhRMA sues Trump administration over Medicare Part B drug pricing model
4
Dupilumab linked to lower risk of new allergic conditions in children with atopic dermatitis | Fall Clinical Derm 2026
5